Recent investigations have converged on the overlap of GLP-1|GIP|GCGR activator therapies and dopaminergic communication. While GCGR agonists are widely employed for treating type 2 diabetes mellitus, their potential https://esmeerdrj308136.thezenweb.com/emerging-gcgr-stimulators-and-dopamine-adjustment-a-contextual-overview-80163959